SecBot SecBot
DEFA14A ·Filed Aug 7, 2026

CDIO

Cardio Diagnostics Holdings, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed2mo ago SEC0001079973-26-001010
Proxy solicitation materials
Actionable Insight • Neutral

This DEFA14A is a routine administrative supplement to prior proxy materials—no new actionable information. Monitor the definitive proxy statement (DEF 14A) for actual voting items and any accompanying SC 13D filings for potential activist activity.

DirectionNeutral
Confidencelow
Horizonimmediate
Latest settled — T+20d
CDIO ▲ +3.91% at T+20d
NEUTRAL call +3.91% · α vs SPY +4.31% · entry $1.79 → $1.86
Next anchor: T+60d in 6d
Latest observation: T+54 +27.70% FF3 residual α
Entry = T+0 close
Aug 7, 2026
via day close
T+1d
-4.47%
call -4.47% · α -4.44%
$1.71
settled 3mo ago
T+5d
+13.97%
call +13.97% · α +13.57%
$2.04
settled 2mo ago
T+20d
+3.91%
call +3.91% · α +4.31%
$1.86
settled 8w ago
T+60d
Pending
in 6d

Price Chart

Loading chart...

Executive Summary

Cardio Diagnostics Holdings filed additional definitive proxy soliciting materials (DEFA14A) on August 7, 2026. The filing is administrative in nature, supplying supplemental graphics and standard SEC cover-page information without disclosing any new substantive proposals, financial terms, or activist demands. The document content is limited to boilerplate EDGAR header metadata and embedded image files, providing no material trading signal.

Key Facts

  • Form DEFA14A filed on August 7, 2026 as additional definitive proxy materials
  • No substantive proxy proposals, financial data, or activist demands disclosed in the filing text
  • Filing contains only SEC cover page, EDGAR metadata, and two embedded graphic images
  • Company has a market cap of approximately $5M with 86% bullish analyst consensus

Financial Impact

No financial figures disclosed in the filing

Risk Factors

  • Absence of substantive content means no immediate trading catalyst
  • Low market cap and high volatility typical of micro-cap diagnostics companies

Market Snapshot

Exchange
Nasdaq
Sector
In Vitro & In Vivo Diagnostic Substances
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001079973-26-001010
Document: 0001079973-26-001010-index-headers.html0001079973-26-001010
Document: 0001079973-26-001010-index.html0001079973-26-001010
Document: 0001079973-26-001010.txt0001079973-26-001010
2 reports for CDIO
Performance horizon
Filters
Rows
Reports for CDIO — sortable, filterable
TypeNow
Aug 20, 2026
9w ago
8-K
NEUTRAL ★ 2/10
$2.21 $2.02▼ −8.60%▼ −8.60%$1.72 (−22.17%)
Aug 7, 2026
11w ago
DEFA14A
NEUTRAL ★ 2/10
$1.79 $1.86▲ +3.91%▲ +4.31%$1.72 (−3.91%)
Showing 2 of 2

US Market Status

Market Closed — Opens in 5h 4m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 7, 2026